icon3

Cardiac Rhythm Management Market : New Products, Positive Clinical Trial Results, Market Overview, Growth Analysis, and Forecast

  • 31
  • |
  • Oct, 2018
  • |
  • Cardiovascular Devices
  • |
  • Pages
  • |
  • Global

Market Overview, Key in-line Products, Market Share Distribution, Competitive Dynamics, Regulatory Outlook, Pipeline Development, Growth Catalysts & Challenges, Leading Market & R&D Trends, Partnership & Deals Analyses, Global Sales forecast of in-line and pipeline products, Fast Growing Private Companies, Management Perspectives, Commentaries, Market Outlook & Summary Conclusions
   
Global CRM market was valued at $10bn in 2015, with two main product categories ICD accounted for an estimated $6.0bn (60%) in sales and the pacemaker the reaming $4.0bn (40%) of the total market. The global CRM market is expected to grow at a modest 5.4% CAGR between 2015 and 2024, culminating in 2024 global sales of $16.8bn.

Cardiac Rhythm management (CRM) represents the largest segment of the cardiovascular devices market. Heart rhythm disorders are fairly common, with millions of people experiencing arrhythmias, or irregular heartbeats, at some point over their lives. Cardiac rhythm management (CRM) accounts for nearly 30% of worldwide death caused by cardiovascular disease. Nearly 7 million deaths occur in Germany, Italy, France, UK, & Spain annually due to sudden cardiac arrest (SCA).

In the early 2000s, the ICD market was a growth market driven by the launch of new products, positive clinical trial results, and indication expansions. However, after several recalls, government investigations, and journal articles raising the issue of overuse, the market slowed and has since become a mature market. The pacemaker market has been a more mature market for some time though in recent years has come under some more pressure amid a deteriorating pricing environment.

Market Overview, Key in-line Products, Market Share Distribution, Competitive Dynamics, Regulatory Outlook, Pipeline Development, Growth Catalysts & Challenges, Leading Market & R&D Trends, Partnership & Deals Analyses, Global Sales forecast of in-line and pipeline products, Fast Growing Private Companies, Management Perspectives, Commentaries, Market Outlook & Summary Conclusions
   
Global CRM market was valued at $10bn in 2015, with two main product categories ICD accounted for an estimated $6.0bn (60%) in sales and the pacemaker the reaming $4.0bn (40%) of the total market. The global CRM market is expected to grow at a modest 5.4% CAGR between 2015 and 2024, culminating in 2024 global sales of $16.8bn.

Cardiac Rhythm management (CRM) represents the largest segment of the cardiovascular devices market. Heart rhythm disorders are fairly common, with millions of people experiencing arrhythmias, or irregular heartbeats, at some point over their lives. Cardiac rhythm management (CRM) accounts for nearly 30% of worldwide death caused by cardiovascular disease. Nearly 7 million deaths occur in Germany, Italy, France, UK, & Spain annually due to sudden cardiac arrest (SCA).

In the early 2000s, the ICD market was a growth market driven by the launch of new products, positive clinical trial results, and indication expansions. However, after several recalls, government investigations, and journal articles raising the issue of overuse, the market slowed and has since become a mature market. The pacemaker market has been a more mature market for some time though in recent years has come under some more pressure amid a deteriorating pricing environment.


REPORT YOU MIGHT BE INTERESTED

Contact Us

Email Us at: sales@optimainsights.org | Reach Us at: +91 966 6620 365 | +1 424 2554 365 (US)